<img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=586106&amp;fmt=gif">


Posted by James Tannahill

On 04/10/19 [07:51], Rumor Hound alerted potential takeover of The Medicines Company, (Nasdaq:GSM, $28.45) where no potential acquirer was mentioned. This ‘MDCO takeover’ rumor may be rooted in a note published by Citigroup Inc. (NYSE, C, $65.48) analyst regarding expectation of near-term PhIII safety data from ORION program (particularly ORION-10) evaluating lead candidate Inclisiran, a small interfering ribonucleic acid (siRNA) therapy to lower low-density lipoprotein cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease (ASCVD).


Importantly, Inclisiran represents a novel approach to lowering LDL-C, as SOC statins have fallen short for preventing second event of disease and lowering mortality (partly due to lack of adherence) in populations with cardiovascular disease (CVD)- of which 12.7 million Americans could potentially benefit. Inclisiran can be administered twice annually versus SOC’s daily regimen and exhibits 1) durable and 2) long efficacy to date supported in part by ORION-1 PhII data published in NEJM) suggesting 56% peak LDL-C reduction at 300mg dosing in high-risk population. PhII data was formerly presented at 2017 American College of Cardiology Annual Meeting.


This takeover rumor may be substantiated by


1) Rumor Hound highest source popularity and source reliability scores of 6.33 and 10, respectively,

2) Likelihood of 2H19 MAA and NDA submissions for Inclisiran,

3) Somewhat universal, positive outlooks/ratings from Street analysts regarding drug’s robust safety and efficacy profile, and

4) View that MDCO offers a robust therapy- with near-term data that could pave way to marketing approvals- allowing drug to rapidly fulfill unmet needs in CVD spanning multiple populations globally.


About The Medicines Company

The Medicines Company is a biopharmaceutical company with a singular, relentless focus on addressing the greatest global healthcare challenge and burden today – cardiovascular disease. Our purpose is to halt the deadly progression of atherosclerosis and the cardiovascular risk created by high levels of LDL-C, or bad cholesterol. The Company is headquartered in Parsippany, New Jersey. For more information, please visit www.themedicinescompany.com and follow us on Twitter @MDCONews.

Topics: Rumor Hound